AR069636A1 - TRIAZOLO TRIAZINAS AND TRIAZOLOPIRAZINAS REPLACED, PROCEDURE FOR THEIR PREPARATION, MEDICATIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT AND / OR PROFILAXIS OF HEMATOLOGICAL DISORDERS, SUCH AS NEUTROPENIAS AND LEUCOPENIAS. - Google Patents

TRIAZOLO TRIAZINAS AND TRIAZOLOPIRAZINAS REPLACED, PROCEDURE FOR THEIR PREPARATION, MEDICATIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT AND / OR PROFILAXIS OF HEMATOLOGICAL DISORDERS, SUCH AS NEUTROPENIAS AND LEUCOPENIAS.

Info

Publication number
AR069636A1
AR069636A1 ARP080105333A ARP080105333A AR069636A1 AR 069636 A1 AR069636 A1 AR 069636A1 AR P080105333 A ARP080105333 A AR P080105333A AR P080105333 A ARP080105333 A AR P080105333A AR 069636 A1 AR069636 A1 AR 069636A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
amino
aminocarbonyl
carbonyl
Prior art date
Application number
ARP080105333A
Other languages
Spanish (es)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102007060172A external-priority patent/DE102007060172A1/en
Priority claimed from DE200810035209 external-priority patent/DE102008035209A1/en
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR069636A1 publication Critical patent/AR069636A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Reivindicacion 1: Compuesto de la formula (1) en la que u representa N, V representa CR12, w representa N, A representa CR15; o u representa N, v representa N, w representa CR16, A representa N, donde R12 representa hidrogeno, hidroxilo, amino, hidroxicarbonilo, aminocarbonilo, trifluorometilo, trifluorometoxi, ciano, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, (alquil C1-4)carbonilamino, alquil C1-4-sulfonilamino, heterociclilcarbonilo de 5 o 6 miembros, -CH2R13 o -CH2CH2R14, donde heterociclilcarbonilo está sustituido con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, oxo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)-carbonilo y (alquil C1-4)aminocarbonilo, y donde alcoxi, alquilamino, alquilcarbonilo, alcoxicarbonilo, alquilaminocarbonilo, alquilcarbonilamino y alquilsulfonilamino pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por hidroxilo, amino, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, alquil C1-4-carbonilamino, heterociclilo de 5 o 6 miembros y fenilo, donde fenilo puede estar sustituido con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, ciano, trifluorometilo, trifluorometoxi, aminocarbonilo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y (alquil C1-4)carbonilamino, y donde heterociclilo puede estar sustituido con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, oxo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)-carbonilo y (alquil C1-4)aminocarbonilo, y donde R13 representa hidroxilo, amino, ciano, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, (alquil C1-4)carbonilamino o heterociclilo de 5 o 6 miembros, donde alcoxi, alquilamino, alcoxicarbonilo, alquilaminocarbonilo y alquilcarbonilamino pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por hidroxilo, amino, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y (alquil C1-4)carbonilamino, y donde heterociclilo puede estar sustituido con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, oxo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)-carbonilo y (alquil C1-4)aminocarbonilo, y donde R14 representa hidroxilo, amino, ciano, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, (alquil C1-4)carbonilamino o heterociclilo de 5 o 6 miembros, donde alcoxi, alquilamino, alcoxicarbonilo, alquilaminocarbonilo y alquilcarbonilamino pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por hidroxilo, amino, hidroxicarbonilo, aminocarbonilo, alcoxi C1-4, (alquil C1-4)amino, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y (alquil C1-4)carbonilamino, y donde heterociclilo puede estar sustituido con 1 a 2 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, oxo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)-carbonilo y (alquil C1-4)aminocarbonilo, R15 representa hidrogeno, halogeno, ciano, trifluorometilo, alquilo C1-3, metoxi, metiltio o ciclopropilo, R16 representa hidrogeno o metilo; representa un resto del grupo de formulas (2) en las que * es el punto de union al heterociclo, n representa el numero 0 o 1; X representa NR10, S u O, donde R10 representa hidrogeno, alquilo C1-3 o ciclopropilo, Y representa NR11 o S, donde R11 representa hidrogeno, alquilo C1-3 o ciclopropilo, R3 representa pirid-2-ilo, pirimid-2-ilo, 2-aminopirimid-4-ilo, 2-(mono-(alquil C1-4)-amino)pirimid-4-ilo, 2-(mono-cicloalquilamino C3-4)pirimid-4-ilo, piridazin-3(2H)-on-6-ilo; 1,3-oxazol-2-ilo, 1,3-oxazol-4-ilo, 1,2,4-oxadiazol-3-ilo, 1,2,3-oxadiazol-4-ilo, 1,3-tiazol-2-ilo, 1,3-tiazol-4-ilo, 1H-1,2,4-triazol-5-ilo, 2,4-dihidro-3H-1,2,4-triazol-3-on-5-ilo o 1,2-pirazol-5-ilo, donde pirid-2-ilo, pirimid-2-ilo, 1,3-oxazol-2-ilo, 1,3-oxazol-4-ilo, 1,3-tiazol-2-ilo y 1,3-tiazol-4-ilo están sustituidos con 1 o 2 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, ciano, nitro, amino, trifluorometilo, trifluorometoxi, aminocarbonilo, trifluorometilcarbonilo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, cicloalquilamino C3-4, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y ciclo alquilcarbonilo C3-6, donde alquilo, alcoxi, alquilamino, alquilcarbonilo, alcoxicarbonilo, alquilaminocarbonilo y cicloalquilcarbonilo pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por halogeno, ciano, hidroxilo, amino, trifluorometilo y cicloalquilo C3-5, y donde 2-aminopirimid-4-ilo, 2-(mono-(alquil C1-4)-amino)pirimid-4-ilo, 2-(mono-C3-4-cicloalquilamino)pirinlid-4-ilo, piridazin-3(2H)-on-6-ilo, 1,2,4-oxadiazol-3-ilo, 1,2,3-oxadiazol-4-ilo, 1H-1,2,4-triazol-5-ilo, 2,4-dihidro-3H-1,2,4-triazol-3-on-5-ilo y 1,2-pirazol-5-ilo pueden estar sustituidos con un sustituyente, seleccionándose el sustituyente del grupo constituido por halogeno, ciano, nitro, amino, trifluorometilo, trifluorometoxi, aminocarbonilo, trifluorometilcarbonilo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, cicloalquilamino C3-4, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y cicloalquilcarbonilo C3-6, R4 representa hidrogeno, alquilo C1-3 o ciclopropilo, R5 representa hidrogeno o alquilo C1-3, R6 representa hidrogeno, alquilo C1-3 o ciclopropilo, R7 representa hidrogeno o alquilo C1-3, R8 representa hidrogeno, alquilo C1-3 o ciclopropilo, R9 representa hidrogeno o alquilo C1-3, R2 representa arilo C5-10 o heteroarilo de 5 a 10 miembros, donde arilo y heteroarilo pueden estar sustituidos con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por hidroxilo, hidroximetilo, amino, halogeno, ciano, trifluorometilo, trifluorometoxi, aminocarbonilo, alquilo C1-4, alcoxi C1-4, (alcoxi C1-4)metilo, (alquil C1-4)amino, (alquil C1-4)-aminometilo, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo, (alquil C1-4)carbonilamino, (alquil C1-4)sulfonilo, (alquil C1-4)sulfonilamino, (alquil C1-4)-aminosulfonilo, fenilo, benciloxi, heterociclilo de 5 o 6 miembros, heterociclilcarbonilo de 5 o 6 miembros, heterociclilmetilo de 5 o 6 miembros y heteroarilo de 5 o 6 miembros, donde fenilo, benciloxi, heterociclilo, heterociclilcarbonilo, heterociclilmetilo y heteroarilo pueden estar sustituidos con 1 a 3 sustituyentes, seleccionándose los sustituyentes independientemente uno de otro del grupo constituido por halogeno, ciano, trifluorometilo, trifluorometoxi, aminocarbonilo, alquilo C1-4, alcoxi C1-4, (alquil C1-4)amino, (alquil C1-4)carbonilo, (alcoxi C1-4)carbonilo, (alquil C1-4)aminocarbonilo y (alquil C1-4)carbonilamino, o dos de los sustituyentes en arilo junto con los átomos de carbono a los que están unidos forman un 1,3-dioxolano o 1,4-dioxano; o una de sus sales, sus solvatos o los solvatos de sus sales.Claim 1: Compound of the formula (1) wherein u represents N, V represents CR12, w represents N, A represents CR15; ou represents N, v represents N, w represents CR16, A represents N, where R12 represents hydrogen, hydroxy, amino, hydroxycarbonyl, aminocarbonyl, trifluoromethyl, trifluoromethoxy, cyano, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl ) amino, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl, (C1-4 alkyl) carbonylamino, C1-4 alkyl sulfonylamino, 5- or 6-membered heterocyclylcarbonyl, - CH2R13 or -CH2CH2R14, where heterocyclylcarbonyl is substituted with 1 to 3 substituents, the substituents being independently selected from each other from the group consisting of halogen, oxo, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl) amino, (alkyl C1-4) carbonyl, (C1-4 alkoxy) -carbonyl and (C1-4 alkyl) aminocarbonyl, and wherein alkoxy, alkylamino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl, alkylcarbonylamino and alkylsulfonylamino may be substituted with a substituent, the substituent being selected from the group consisting of hydroxyl, amino, hydroxycarb onyl, aminocarbonyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl, C1-4 alkylcarbonylamino, 5- or 6-membered heterocyclyl and phenyl, where Phenyl may be substituted with 1 to 3 substituents, the substituents being independently selected from each other from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, aminocarbonyl, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl) amino, ( C1-4 alkyl) carbonyl, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl and (C1-4 alkyl) carbonylamino, and where heterocyclyl can be substituted with 1 to 3 substituents, the substituents being independently selected from each other from the group consisting of halogen, oxo, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) -carbonyl and (C1-4 alkyl) aminocarbonyl , and where R13 represents hydroxyl, amino, cyano, hydroxycarbonyl, aminocarbonyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkoxy) carbonyl, (alkyl C1-4) aminocarbonyl, (C1-4 alkyl) carbonylamino or 5- or 6-membered heterocyclyl, wherein alkoxy, alkylamino, alkoxycarbonyl, alkylaminocarbonyl and alkylcarbonylamino may be substituted with a substituent, the substituent being selected from the group consisting of hydroxyl, amino, hydroxycarbonyl , aminocarbonyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl and (C1-4 alkyl) carbonylamino, and where heterocyclyl can be substituted with 1 to 3 substituents, the substituents being independently selected from each other from the group consisting of halogen, oxo, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) - carbonyl and (C1-4 alkyl) aminocarbonyl, and where R14 represents hydroxyl, amino, cyano, hydroxycarbonyl, aminocarbonyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkoxy) carbonyl, (C1-4 alkyl ) aminocarbonyl, (C 1-4 alkyl) carbonylamino or 5- or 6-membered heterocyclyl, where alkoxy, alkylamin or, alkoxycarbonyl, alkylaminocarbonyl and alkylcarbonylamino may be substituted with a substituent, the substituent being selected from the group consisting of hydroxyl, amino, hydroxycarbonyl, aminocarbonyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl and (C1-4 alkyl) carbonylamino, and where heterocyclyl can be substituted with 1 to 2 substituents, the substituents being independently selected from each other from the group consisting of halogen, oxo, C1-4 alkyl, C1 alkoxy -4, (C1-4 alkyl) amino, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) -carbonyl and (C1-4 alkyl) aminocarbonyl, R15 represents hydrogen, halogen, cyano, trifluoromethyl, C1-3 alkyl , methoxy, methylthio or cyclopropyl, R16 represents hydrogen or methyl; represents a remainder of the group of formulas (2) in which * is the point of attachment to the heterocycle, n represents the number 0 or 1; X represents NR10, S or O, where R10 represents hydrogen, C1-3 alkyl or cyclopropyl, Y represents NR11 or S, where R11 represents hydrogen, C1-3 alkyl or cyclopropyl, R3 represents pyrid-2-yl, pyrimid-2- ilo, 2-aminopyrimid-4-yl, 2- (mono- (C1-4 alkyl) -amino) pyrimid-4-yl, 2- (mono-C3-4 cycloalkylamino) pyrimid-4-yl, pyridazin-3 ( 2H) -on-6-yl; 1,3-oxazol-2-yl, 1,3-oxazol-4-yl, 1,2,4-oxadiazol-3-yl, 1,2,3-oxadiazol-4-yl, 1,3-thiazole- 2-yl, 1,3-thiazol-4-yl, 1H-1,2,4-triazol-5-yl, 2,4-dihydro-3H-1,2,4-triazol-3-on-5- yl or 1,2-pyrazol-5-yl, where pyrid-2-yl, pyrimid-2-yl, 1,3-oxazol-2-yl, 1,3-oxazol-4-yl, 1,3-thiazole -2-yl and 1,3-thiazol-4-yl are substituted with 1 or 2 substituents, the substituents being selected independently from each other from the group consisting of halogen, cyano, nitro, amino, trifluoromethyl, trifluoromethoxy, aminocarbonyl, trifluoromethylcarbonyl, alkyl C1-4, C1-4 alkoxy, (C1-4 alkyl) amino, C3-4 cycloalkylamino, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl and C3- alkylcarbonyl cycle 6, where alkyl, alkoxy, alkylamino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl and cycloalkylcarbonyl may be substituted with a substituent, the substituent being selected from the group consisting of halogen, cyano, hydroxyl, amino, trifluoromethyl and c C3-5 icloalkyl, and where 2-aminopyrimid-4-yl, 2- (mono- (C1-4 alkyl) -amino) pyrimid-4-yl, 2- (mono-C3-4-cycloalkylamino) pyrinlid-4- ilo, pyridazin-3 (2H) -on-6-yl, 1,2,4-oxadiazol-3-yl, 1,2,3-oxadiazol-4-yl, 1H-1,2,4-triazol-5 -yl, 2,4-dihydro-3H-1,2,4-triazol-3-on-5-yl and 1,2-pyrazol-5-yl may be substituted with a substituent, the substituent being selected from the group consisting of halogen, cyano, nitro, amino, trifluoromethyl, trifluoromethoxy, aminocarbonyl, trifluoromethylcarbonyl, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl) amino, C3-4 cycloalkylamino, (C1-4 alkoxy) carbonyl, (C1 alkyl -4) aminocarbonyl and C3-6 cycloalkylcarbonyl, R4 represents hydrogen, C1-3 alkyl or cyclopropyl, R5 represents hydrogen or C1-3 alkyl, R6 represents hydrogen, C1-3 alkyl or cyclopropyl, R7 represents hydrogen or C1-3 alkyl, R8 represents hydrogen, C1-3 alkyl or cyclopropyl, R9 represents hydrogen or C1-3 alkyl, R2 represents C5-10 aryl or 5-10 membered heteroaryl, where of aryl and heteroaryl may be substituted with 1 to 3 substituents, the substituents being selected independently from each other from the group consisting of hydroxy, hydroxymethyl, amino, halogen, cyano, trifluoromethyl, trifluoromethoxy, aminocarbonyl, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkoxy) methyl, (C1-4 alkyl) amino, (C1-4 alkyl) -aminomethyl, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl, ( C1-4 alkyl) carbonylamino, (C1-4 alkyl) sulfonyl, (C1-4 alkyl) sulfonylamino, (C1-4 alkyl) -aminosulfonyl, phenyl, benzyloxy, 5- or 6-membered heterocyclyl, 5- or 6-membered heterocyclylcarbonyl, 5 or 6-membered heterocyclylmethyl and 5 or 6-membered heteroaryl, where phenyl, benzyloxy, heterocyclyl, heterocyclylcarbonyl, heterocyclylmethyl and heteroaryl may be substituted with 1 to 3 substituents, the substituents being independently selected from each other from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, a minocarbonyl, C1-4 alkyl, C1-4 alkoxy, (C1-4 alkyl) amino, (C1-4 alkyl) carbonyl, (C1-4 alkoxy) carbonyl, (C1-4 alkyl) aminocarbonyl and (C1-4 alkyl) carbonylamino, or two of the aryl substituents together with the carbon atoms to which they are attached form a 1,3-dioxolane or 1,4-dioxane; or one of its salts, its solvates or the solvates of its salts.

ARP080105333A 2007-12-13 2008-12-09 TRIAZOLO TRIAZINAS AND TRIAZOLOPIRAZINAS REPLACED, PROCEDURE FOR THEIR PREPARATION, MEDICATIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT AND / OR PROFILAXIS OF HEMATOLOGICAL DISORDERS, SUCH AS NEUTROPENIAS AND LEUCOPENIAS. AR069636A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007060172A DE102007060172A1 (en) 2007-12-13 2007-12-13 New nitrogen substituted heterocyclic compounds are glycogen synthase kinase 3-beta inhibitors useful e.g. to treat and/or prevent hematological disease, preferably leukopenia, and for ex-vivo increase of adult hematopoietic stem cells
DE200810035209 DE102008035209A1 (en) 2008-07-29 2008-07-29 New nitrogen substituted heterocyclic compounds are glycogen synthase kinase 3-beta inhibitors useful e.g. to treat and/or prevent hematological disease, preferably leukopenia, and for ex-vivo increase of adult hematopoietic stem cells

Publications (1)

Publication Number Publication Date
AR069636A1 true AR069636A1 (en) 2010-02-10

Family

ID=40578190

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105333A AR069636A1 (en) 2007-12-13 2008-12-09 TRIAZOLO TRIAZINAS AND TRIAZOLOPIRAZINAS REPLACED, PROCEDURE FOR THEIR PREPARATION, MEDICATIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT AND / OR PROFILAXIS OF HEMATOLOGICAL DISORDERS, SUCH AS NEUTROPENIAS AND LEUCOPENIAS.

Country Status (11)

Country Link
US (1) US20090258877A1 (en)
EP (1) EP2229392A1 (en)
JP (1) JP2011506364A (en)
AR (1) AR069636A1 (en)
CA (1) CA2708783A1 (en)
CL (1) CL2008003602A1 (en)
PA (1) PA8806501A1 (en)
PE (1) PE20091074A1 (en)
TW (1) TW200938546A (en)
UY (1) UY31508A1 (en)
WO (1) WO2009074259A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434972C (en) 2001-01-16 2010-06-08 Vascular Therapies, Llc Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
CN112384515A (en) 2018-02-27 2021-02-19 因赛特公司 Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors
MX2020012376A (en) 2018-05-18 2021-03-09 Incyte Corp Fused pyrimidine derivatives as a2a / a2b inhibitors.
EP3818063A1 (en) 2018-07-05 2021-05-12 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60236322D1 (en) * 2001-12-07 2010-06-17 Vertex Pharma PYRIMIDIN-BASED COMPOUNDS AS A GSK-3 HEMMER
EP1543008B1 (en) * 2002-09-23 2007-11-07 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
ATE369370T1 (en) * 2003-10-10 2007-08-15 Pfizer Prod Inc SUBSTITUTED 2H-(1,2,4)TRIAZOLO(4,3-A)PYRAZINE AS GSK-3 INHIBITORS
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors

Also Published As

Publication number Publication date
US20090258877A1 (en) 2009-10-15
PA8806501A1 (en) 2009-08-26
PE20091074A1 (en) 2009-07-26
CL2008003602A1 (en) 2009-10-09
WO2009074259A1 (en) 2009-06-18
TW200938546A (en) 2009-09-16
EP2229392A1 (en) 2010-09-22
UY31508A1 (en) 2009-08-03
JP2011506364A (en) 2011-03-03
CA2708783A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
AR069636A1 (en) TRIAZOLO TRIAZINAS AND TRIAZOLOPIRAZINAS REPLACED, PROCEDURE FOR THEIR PREPARATION, MEDICATIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT AND / OR PROFILAXIS OF HEMATOLOGICAL DISORDERS, SUCH AS NEUTROPENIAS AND LEUCOPENIAS.
AR050364A1 (en) DERIVATIVES OF SULFONAMIDS, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
AR078168A1 (en) DERIVATIVES OF PIPERIDINS AND PIPERAZINS, PROCESSES TO PREPARE THEM AND THEIR USES AS MODULATORS OF GPR119
AR065719A1 (en) IMIDAZO AND TRIAZOLOPIRIMIDINAS, A PROCEDURE FOR ITS PREPARATION AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HEMATOLOGICAL DISORDERS.
AR047538A1 (en) PIRIDAZINONAS AS ANTAGONISTS OF THE INTEGRINES ALFA4
AR045747A1 (en) DERIVATIVES OF 2,4 DI (IET) -ARILAMINO-PYRIMIDINE AS ZAP-70 INHIBITORS
AR073369A1 (en) DERIVATIVES OF 2-CARBOXAMIDA-CICLOAMINO-UREA AS PI-3 INHIBITORS
PE20230820A1 (en) BIARYL DERIVATIVES AS INHIBITORS OF YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION
AR069417A1 (en) PIPERIDINAS HETEROARIL - SUBSTITUTED
AR048495A1 (en) BENZOIL AMINO HETEROCICLICOS, USEFUL FOR THE TREATMENT OF GLK INTERMEDIATE DISEASES
AR050540A1 (en) DERIVATIVES OF TRICICLIC ADAMANTILAMIDE AS INHIBITORS OF DEHYDROGENASE 11- BETA HYDROXYSTEROID
PE20091429A1 (en) 4- (4-CYANE-2-THIOARIL) DIHYDROPYRIMIDINONES AS INHIBITORS OF HUMAN NEUTROPHYL ELASTASE (HNE)
CO6140033A2 (en) AMINO-IMIDAZOLES AND ITS USE AS A MEDICINAL PRODUCT TO TREAT COOGNOTIVE DISABILITY ALZHEIMER NEURODEGENERATION AND DEMENTIA DISEASE
AR076908A1 (en) ARIL-PYRIDINS AS INHIBITORS OF SINTASA DE ALDOSTERONA
RU2009118602A (en) DERIVATIVE INDOLA
AR067327A1 (en) PIPERIDINE / PIPERAZINE DERIVATIVES
CO6300864A2 (en) POLISUSTITUTED DERIVATIVES OF 6-HETEROARIL-IMIDAZO [1,2-A] PIRIDINES ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
CO6251263A2 (en) DERIVATIVES OF BENCIMIDAZOL AND INDOL SUBJECTED BY OXADIAZOL AND OXAZOL AS INHIBITORS OF DGAT1
AR075868A1 (en) 2-ACETAMIDO-5-ARIL-1,2,4-SUBSTITUTED TRIAZOLONS AND ITS USE
AR082888A1 (en) PIRIDINE COMPOUNDS FOR THE INHIBITION OF NAMPT
PE20190806A1 (en) HETEROCYCLIC AGONISTS OF THE APELINE RECEPTOR (JPA) AND USES OF THEM
AR059493A1 (en) ERK INHIBITING COMPOUNDS
AR059895A1 (en) BICYCLE DERIVATIVES OF CARBOXYLIC ACIDS THAT RESULT IN USEFULNESS TO TREAT METABOLIC DISORDERS
AR073687A1 (en) CB2 RECEIVER AGONISTS, DERIVATIVES OF OXAZOLES AND / OR TRIAZOLS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF PAIN, AUTOIMMUNE AND ALLERGIC DISEASES, AMONG OTHERS.
AR044078A1 (en) SUBSTITUTED DIHYDROQUINAZOLINS

Legal Events

Date Code Title Description
FB Suspension of granting procedure